Sections
| Title | Starting Page | Number of Pages |
|---|
| Introduction | 2 | 1 |
| Table of Contents | 2 | 31 |
| List of Tables | 27 | 4 |
| List of Figures | 31 | 1 |
| Global Markets Direct Report Coverage | 32 | 1 |
| Type 1 diabetes (Juvenile Diabetes) Overview | 33 | 1 |
| Therapeutics Development | 34 | 2 |
| Pipeline Products for Type 1 diabetes (Juvenile Diabetes) Overview | 34 | 1 |
| Pipeline Products for Type 1 diabetes (Juvenile Diabetes) Comparative Analysis | 35 | 1 |
| Type 1 diabetes (Juvenile Diabetes) Therapeutics under Development by Companies | 36 | 9 |
| Type 1 diabetes (Juvenile Diabetes) Therapeutics under Investigation by Universities/Institutes | 45 | 2 |
| Type 1 diabetes (Juvenile Diabetes) Pipeline Products Glance | 47 | 4 |
| Late Stage Products | 47 | 1 |
| Clinical Stage Products | 48 | 1 |
| Early Stage Products | 49 | 1 |
| Unknown Stage Products | 50 | 1 |
| Type 1 diabetes (Juvenile Diabetes) Products under Development by Companies | 51 | 13 |
| Type 1 diabetes (Juvenile Diabetes) Products under Investigation by Universities/Institutes | 64 | 2 |
| Type 1 diabetes (Juvenile Diabetes) Companies Involved in Therapeutics Development | 66 | 104 |
| AbGenomics International, Inc. | 66 | 1 |
| Adocia | 67 | 1 |
| AiCuris GmbH &Co. KG | 68 | 1 |
| Alteogen Inc. | 69 | 1 |
| Amarantus Bioscience Holdings, Inc. | 70 | 1 |
| Ambrx, Inc. | 71 | 1 |
| AntriaBio, Inc. | 72 | 1 |
| Aphios Corporation | 73 | 1 |
| APT Therapeutics, Inc. | 74 | 1 |
| Araim Pharmaceuticals, Inc. | 75 | 1 |
| Argos Therapeutics, Inc. | 76 | 1 |
| Artery Therapeutics, Inc. | 77 | 1 |
| Astellas Pharma Inc. | 78 | 1 |
| AstraZeneca Plc | 79 | 1 |
| Athersys, Inc. | 80 | 1 |
| Axxam SpA | 81 | 1 |
| Beta-Cell NV | 82 | 1 |
| Biocon Limited | 83 | 1 |
| Biodel Inc. | 84 | 1 |
| Biogenomics Limited | 85 | 1 |
| BioLineRx, Ltd. | 86 | 1 |
| BioLingus AG | 87 | 1 |
| BioTherapeutics Inc. | 88 | 1 |
| Boehringer Ingelheim GmbH | 89 | 1 |
| Caladrius Biosciences, Inc. | 90 | 1 |
| Carlina Technologies SAS | 91 | 1 |
| Cellectis S.A. | 92 | 1 |
| Compugen Ltd. | 93 | 1 |
| Daewoong Pharmaceutical Co., Ltd. | 94 | 1 |
| Dance Biopharm Inc. | 95 | 1 |
| Diabetology (Products) Ltd | 96 | 1 |
| DiaMedica Inc. | 97 | 1 |
| Diamyd Medical AB | 98 | 1 |
| Diasome Pharmaceuticals, Inc. | 99 | 1 |
| Dompe Farmaceutici S.p.A. | 100 | 1 |
| Effimune S.A. | 101 | 1 |
| Eli Lilly and Company | 102 | 1 |
| enGene, Inc | 103 | 1 |
| Ensol Biosciences Inc. | 104 | 1 |
| EpiVax, Inc. | 105 | 1 |
| Evotec AG | 106 | 1 |
| F. Hoffmann-La Roche Ltd. | 107 | 1 |
| Fate Therapeutics, Inc. | 108 | 1 |
| Generex Biotechnology Corporation | 109 | 1 |
| GeNeuro SA | 110 | 1 |
| Geropharm | 111 | 1 |
| Gilead Sciences, Inc. | 112 | 1 |
| GlaxoSmithKline Plc | 113 | 1 |
| Grifols, S.A. | 114 | 1 |
| Heptares Therapeutics Limited | 115 | 1 |
| Iltoo Pharma | 116 | 1 |
| Innopharmax Inc. | 117 | 1 |
| IntelliCell BioSciences Inc. | 118 | 1 |
| Intrexon Corporation | 119 | 1 |
| Islet Sciences, Inc. | 120 | 1 |
| Johnson &Johnson | 121 | 1 |
| Kadimastem Ltd. | 122 | 1 |
| Kamada Ltd. | 123 | 1 |
| Kasiak Research Private Limited | 124 | 1 |
| Kineta, Inc. | 125 | 1 |
| Kissei Pharmaceutical Co., Ltd. | 126 | 1 |
| Lexicon Pharmaceuticals, Inc. | 127 | 1 |
| Ligand Pharmaceuticals, Inc. | 128 | 1 |
| Lonestar Heart, Inc. | 129 | 1 |
| MacroGenics, Inc. | 130 | 1 |
| Medestea Research &Production S.p.A. | 131 | 1 |
| MedImmune, LLC | 132 | 1 |
| Merck &Co., Inc. | 133 | 1 |
| Meridigen Biotech Co., Ltd. | 134 | 1 |
| MidaSol Therapeutics LP | 135 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 136 | 1 |
| NOD Pharmaceuticals, Inc. | 137 | 1 |
| Novo Nordisk A/S | 138 | 1 |
| Noxxon Pharma AG | 139 | 1 |
| Oramed Pharmaceuticals, Inc. | 140 | 1 |
| Orgenesis, Inc. | 141 | 1 |
| Paras Biopharmaceuticals Finland Oy | 142 | 1 |
| Parvus Therapeutics, Inc. | 143 | 1 |
| Pathfinder Cell Therapy, Inc. | 144 | 1 |
| Pfizer Inc. | 145 | 1 |
| PharmaCyte Biotech, Inc. | 146 | 1 |
| PharmaIN Corporation | 147 | 1 |
| Progen Pharmaceuticals Limited | 148 | 1 |
| Prometheon Pharma, LLC | 149 | 1 |
| Purzer Pharmaceutical Co., Ltd. | 150 | 1 |
| RedHill Biopharma Ltd. | 151 | 1 |
| REGiMMUNE Corporation | 152 | 1 |
| Sanofi | 153 | 1 |
| SEKRIS Biomedical, Inc. | 154 | 1 |
| Selecta Biosciences, Inc. | 155 | 1 |
| Sevion Therapeutics, Inc. | 156 | 1 |
| Strongbridge Biopharma plc | 157 | 1 |
| Therapix Biosciences Ltd | 158 | 1 |
| Thermalin Diabetes, LLC | 159 | 1 |
| Toleranzia AB | 160 | 1 |
| Transgene Biotek Limited | 161 | 1 |
| UCB S.A. | 162 | 1 |
| Uni-Bio Science Group Ltd. | 163 | 1 |
| United Therapeutics Corporation | 164 | 1 |
| ViaCyte, Inc. | 165 | 1 |
| Visionary Pharmaceuticals, Inc. | 166 | 1 |
| XL-protein GmbH | 167 | 1 |
| XOMA Corporation | 168 | 1 |
| Zensun (Shanghai) Sci &Tech Co., Ltd. | 169 | 1 |
| Type 1 diabetes (Juvenile Diabetes) Therapeutics Assessment | 170 | 15 |
| Assessment by Monotherapy Products | 170 | 1 |
| Assessment by Combination Products | 171 | 1 |
| Assessment by Target | 172 | 5 |
| Assessment by Mechanism of Action | 177 | 4 |
| Assessment by Route of Administration | 181 | 2 |
| Assessment by Molecule Type | 183 | 2 |
| Drug Profiles | 185 | 447 |
| (clarithromycin + clofazimine + rifabutin) - Drug Profile | 185 | 3 |
| Product Description | 185 | 1 |
| Mechanism of Action | 185 | 1 |
| R&D Progress | 185 | 3 |
| (cyclosporine + lansoprazole) - Drug Profile | 188 | 1 |
| Product Description | 188 | 1 |
| Mechanism of Action | 188 | 1 |
| R&D Progress | 188 | 1 |
| (Glucagon-Like Peptide-1 + insulin human) - Drug Profile | 189 | 1 |
| Product Description | 189 | 1 |
| Mechanism of Action | 189 | 1 |
| R&D Progress | 189 | 1 |
| (insulin aspart + insulin aspart protamine) - Drug Profile | 190 | 1 |
| Product Description | 190 | 1 |
| Mechanism of Action | 190 | 1 |
| R&D Progress | 190 | 1 |
| (insulin aspart + insulin degludec) - Drug Profile | 191 | 2 |
| Product Description | 191 | 1 |
| Mechanism of Action | 191 | 1 |
| R&D Progress | 191 | 2 |
| (insulin glargine + insulin glulisine) - Drug Profile | 193 | 1 |
| Product Description | 193 | 1 |
| Mechanism of Action | 193 | 1 |
| R&D Progress | 193 | 1 |
| (insulin glargine + insulin lispro) - Drug Profile | 194 | 1 |
| Product Description | 194 | 1 |
| Mechanism of Action | 194 | 1 |
| R&D Progress | 194 | 1 |
| (insulin human + pramlintide acetate) - Drug Profile | 195 | 1 |
| Product Description | 195 | 1 |
| Mechanism of Action | 195 | 1 |
| R&D Progress | 195 | 1 |
| (insulin lispro + insulin lispro protamine) - Drug Profile | 196 | 1 |
| Product Description | 196 | 1 |
| Mechanism of Action | 196 | 1 |
| R&D Progress | 196 | 1 |
| 2-AMD - Drug Profile | 197 | 1 |
| Product Description | 197 | 1 |
| Mechanism of Action | 197 | 1 |
| R&D Progress | 197 | 1 |
| 4548G-05 - Drug Profile | 198 | 1 |
| Product Description | 198 | 1 |
| Mechanism of Action | 198 | 1 |
| R&D Progress | 198 | 1 |
| AB-101 - Drug Profile | 199 | 1 |
| Product Description | 199 | 1 |
| Mechanism of Action | 199 | 1 |
| R&D Progress | 199 | 1 |
| AbGn-168H - Drug Profile | 200 | 2 |
| Product Description | 200 | 1 |
| Mechanism of Action | 200 | 1 |
| R&D Progress | 200 | 2 |
| ABS-11 - Drug Profile | 202 | 1 |
| Product Description | 202 | 1 |
| Mechanism of Action | 202 | 1 |
| R&D Progress | 202 | 1 |
| AGS-010 - Drug Profile | 203 | 2 |
| Product Description | 203 | 1 |
| Mechanism of Action | 203 | 1 |
| R&D Progress | 203 | 2 |
| AIC-284 - Drug Profile | 205 | 1 |
| Product Description | 205 | 1 |
| Mechanism of Action | 205 | 1 |
| R&D Progress | 205 | 1 |
| AKS-091 - Drug Profile | 206 | 1 |
| Product Description | 206 | 1 |
| Mechanism of Action | 206 | 1 |
| R&D Progress | 206 | 1 |
| albiglutide - Drug Profile | 207 | 3 |
| Product Description | 207 | 1 |
| Mechanism of Action | 207 | 1 |
| R&D Progress | 207 | 3 |
| aldesleukin - Drug Profile | 210 | 1 |
| Product Description | 210 | 1 |
| Mechanism of Action | 210 | 1 |
| R&D Progress | 210 | 1 |
| aldesleukin - Drug Profile | 211 | 1 |
| Product Description | 211 | 1 |
| Mechanism of Action | 211 | 1 |
| R&D Progress | 211 | 1 |
| ALM - Drug Profile | 212 | 1 |
| Product Description | 212 | 1 |
| Mechanism of Action | 212 | 1 |
| R&D Progress | 212 | 1 |
| alpha-1 proteinase inhibitor (human) - Drug Profile | 213 | 1 |
| Product Description | 213 | 1 |
| Mechanism of Action | 213 | 1 |
| R&D Progress | 213 | 1 |
| alpha-1 proteinase inhibitor (human) - Drug Profile | 214 | 2 |
| Product Description | 214 | 1 |
| Mechanism of Action | 214 | 1 |
| R&D Progress | 214 | 2 |
| AMRS-001 - Drug Profile | 216 | 3 |
| Product Description | 216 | 1 |
| Mechanism of Action | 216 | 1 |
| R&D Progress | 216 | 3 |
| Antibody for Neurodegenerative Diseases and Diabetes - Drug Profile | 219 | 1 |
| Product Description | 219 | 1 |
| Mechanism of Action | 219 | 1 |
| R&D Progress | 219 | 1 |
| APH-0907 - Drug Profile | 220 | 1 |
| Product Description | 220 | 1 |
| Mechanism of Action | 220 | 1 |
| R&D Progress | 220 | 1 |
| BetaGRAFT - Drug Profile | 221 | 1 |
| Product Description | 221 | 1 |
| Mechanism of Action | 221 | 1 |
| R&D Progress | 221 | 1 |
| BIOD-531 - Drug Profile | 222 | 2 |
| Product Description | 222 | 1 |
| Mechanism of Action | 222 | 1 |
| R&D Progress | 222 | 2 |
| Biologic to Activate Glutamic Acid Decarboxylase and IL-10 for Type 1 diabetes - Drug Profile | 224 | 1 |
| Product Description | 224 | 1 |
| Mechanism of Action | 224 | 1 |
| R&D Progress | 224 | 1 |
| Biologic to Target Insulin Receptor and IL-10 for Type 1 diabetes - Drug Profile | 225 | 1 |
| Product Description | 225 | 1 |
| Mechanism of Action | 225 | 1 |